News >

Nivolumab Active in Advanced Nasopharyngeal Carcinoma

Jason Harris
Published: Friday, Mar 30, 2018

Brigette B.Y. Ma, MD

Brigette B.Y. Ma, MD
Nivolumab (Opdivo) induced an overall response rate (ORR) of 20.5% in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to results from the phase II NCI-9742 study.

Of the 45 patients who were evaluable for toxicities, 10 (22.2%) experienced grade ≥3 AEs that were possibly related to nivolumab. Grade ≥3 toxicities included colitis, diarrhea, fatigue, increase in aspartate transaminase or alanine aminotransferase levels, neutropenia, hyponatremia, and lymphopenia. One patient died of pulmonary tuberculosis during treatment.
Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742) [published online March 27, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.77.0388.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication